Trial Profile

Pilot Study: Lutetium-177-PSMA-617 in Low Volume Metastatic Prostate Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 10 Feb 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Lutetium (177Lu) vipivotide tetraxetan (Primary)
Indications Adenocarcinoma; Bone metastases; Prostate cancer
Focus Adverse reactions

Most Recent Events

12 Apr 2021 Results assessing toxicity, radiation doses and treatment effect of 17767 Lu-PSMA in low-volume mHSPC patients, published in the Clinical Cancer Research.
13 Nov 2019 Status changed from recruiting to completed.
11 Feb 2019 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com